The DCC protein expression in breast carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The deleted in colon cancer (DCC) gene on chromosome 18 is implicated in colorectal cancer tumorigenesis and metastasis.
• Investigating DCC gene expression in breast cancer provides insights into its potential role in tumorigenesis and prognosis.

Purpose of the Study:

• To examine the expression levels of DCC, P53, and HER-2/neu in invasive breast cancer specimens.
• To evaluate the correlation between DCC expression, P53, and HER-2/neu overexpression, and patient survival outcomes.

Main Methods:

• Immunohistochemistry staining was employed on 79 surgical specimens of invasive breast cancer.
• Patient follow-up data was collected from May 1990 to August 1998, with an average follow-up of 52 months.
• Statistical analysis was performed to assess the influence of gene expression on survival time.

Main Results:

• Decreased DCC expression was observed in 52% of the breast cancer tumors.
• HER-2/neu and P53 overexpression were detected in 36.8% and 32.9% of specimens, respectively.
• A combination of DCC-negative status and HER-2/neu overexpression showed a marginal association with reduced survival time (P=0.06).

Conclusions:

• Reduced DCC expression and HER-2/neu overexpression may be associated with a poorer prognosis in breast cancer patients.
• The combination of DCC-negative and P53 overexpression did not significantly influence breast cancer survival.
• Further research is warranted to elucidate the prognostic significance of DCC and HER-2/neu in breast cancer.